Captor Therapeutics SA (60Q) Stock Price & News

All values in PLN	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	-	44,00 k	328,00 k	1,63 m
Cost of goods sold	-2,02 m	-	-	173,00 k
Cost of revenue	-2,02 m	-	-	173,00 k
Research and development expenses	14,74 m	9,82 m	10,56 m	13,78 m
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1,37 m	2,53 m	1,92 m	2,25 m
Operating expense	13,83 m	10,40 m	11,59 m	14,39 m
Total operating expenses	11,81 m	10,40 m	11,59 m	14,56 m
Operating income	-11,81 m	-10,36 m	-11,26 m	-12,93 m
Other non operating income	1,00 k	-8,00 k	-	-
EBT including unusual items	-11,48 m	-10,05 m	-11,35 m	-11,39 m
EBT excluding unusual items	-11,48 m	-10,12 m	-11,35 m	-11,39 m
Income tax expense	-	-	27,00 k	-
Effective tax rate	-	-	-0,24%	-
Other operating expenses	-2,27 m	-1,94 m	-893,00 k	-1,64 m
Net income	-11,48 m	-10,05 m	-11,38 m	-11,39 m
Net profit margin	-	-22 831,82%	-3 467,99%	-696,88%
Earnings per share	-	-	-	-
Interest and investment income	391,00 k	303,00 k	39,00 k	1,63 m
Interest expense	-61,00 k	-75,00 k	-67,00 k	-57,00 k
Net interest expenses	330,00 k	228,00 k	-28,00 k	1,57 m
Depreciation and amortization charges	-	-	-	-
EBITDA	-10,81 m	-9,53 m	-10,36 m	-12,04 m
Gain or loss from assets sale	-682,00 k	-	-	-128,00 k

Ask anything